Goldman Sachs Group Inc Biomarin Pharmaceutical Inc Call Options Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 13, 2024
BUY
$76.22 - $98.51 $4.21 Million - $5.45 Million
55,300 New
55,300 $5.33 Million
Q3 2022

May 14, 2024
SELL
$82.16 - $96.94 $2.09 Million - $2.46 Million
-25,400 Reduced 45.93%
29,900 $2.54 Million
Q3 2022

Nov 10, 2022
BUY
$82.16 - $96.94 $2.46 Million - $2.9 Million
29,900 New
29,900 $2.53 Million

Others Institutions Holding BMRN

# of Institutions
635
Shares Held
178M
Call Options Held
2.01M
Put Options Held
1.28M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email